✦ LIBER ✦

Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib

✍ Scribed by Mitsuaki Sakai; Shigemi Ishikawa; Hiromichi Ito; Yuichiro Ozawa; Tatsuo Yamamoto; Masataka Onizuka; Yuzuru Sakakibara

Publisher: Springer
Year: 2006
Tongue: English
Weight: 301 KB
Volume: 11
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-005-0558-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Establishment of a human non-small cell

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib

✍ Fumiaki Koizumi; Tatsu Shimoyama; Fumiko Taguchi; Nagahiro Saijo; Kazuto Nishio 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 672 KB

## Abstract The epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor gefitinib (Iressa®, ZD1839) has shown promising activity preclinically and clinically. Because comparative investigations of drug‐resistant sublines with their parental cells are useful approaches to identifying the m

Erlotinib in advanced non-small-cell lun

Erlotinib in advanced non-small-cell lung cancer after gefitinib failure

✍ Zheng-Tao Zhou; Xin-Hua Xu; Qing Wei; Ming-qian Lu; Jie Wang; Cai-Hong Wen 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 262 KB

Gefitinib is effective for pathological

Gefitinib is effective for pathological fracture of metastatic non-small cell lung cancer

✍ Manabu Hoshi; Masatsugu Takami; Makoto Ieguchi; Kunio Takaoka 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 260 KB

Erlotinib as salvage treatment after fai

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

✍ Matthew K. Wong; Alvis I. Lo; Bing Lam; W. K. Lam; Mary S. Ip; James C. Ho 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 197 KB

Gefitinib in the treatment of 41 cases w

Gefitinib in the treatment of 41 cases with refractory non-small cell lung cancer

✍ Jianfang Xu; Caicun Zhou; Aiwu Li 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 76 KB

Gefitinib and chemotherapy combination s

Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response

✍ Jean-Gabriel Judde; Magali Rebucci; Nicolas Vogt; Patricia de Cremoux; Alain Liv 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 458 KB

## Abstract The epidermal growth factor receptor (EGFR) signaling pathway is often activated in NSCLC, and thus represents a promising therapeutic target. We studied the antitumor activity of gefitinib (Iressa™), an orally active EGFR‐tyrosine kinase inhibitor, alone and in combination with standar